Frankfurt - Delayed Quote EUR

Danaher Corporation (DAP.F)

Compare
250.40 -1.90 (-0.75%)
As of 9:52 AM GMT+2. Market Open.
Loading Chart for DAP.F
DELL
  • Previous Close 252.30
  • Open 250.05
  • Bid 250.45 x 60000
  • Ask 251.50 x 60000
  • Day's Range 250.05 - 251.55
  • 52 Week Range 172.30 - 259.20
  • Volume 25
  • Avg. Volume 418
  • Market Cap (intraday) 184.473B
  • Beta (5Y Monthly) 0.86
  • PE Ratio (TTM) 49.98
  • EPS (TTM) 5.01
  • Earnings Date Oct 22, 2024
  • Forward Dividend & Yield 0.97 (0.39%)
  • Ex-Dividend Date Sep 27, 2024
  • 1y Target Est 331.45

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

www.danaher.com

61,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DAP.F

View More

Performance Overview: DAP.F

Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

DAP.F
20.22%
S&P 500
22.47%

1-Year Return

DAP.F
25.87%
S&P 500
33.57%

3-Year Return

DAP.F
10.09%
S&P 500
30.64%

5-Year Return

DAP.F
132.72%
S&P 500
94.85%

Compare To: DAP.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DAP.F

View More

Valuation Measures

Annual
As of 10/16/2024
  • Market Cap

    177.86B

  • Enterprise Value

    191.31B

  • Trailing P/E

    49.13

  • Forward P/E

    30.40

  • PEG Ratio (5yr expected)

    2.64

  • Price/Sales (ttm)

    8.46

  • Price/Book (mrq)

    3.87

  • Enterprise Value/Revenue

    8.83

  • Enterprise Value/EBITDA

    28.62

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.83%

  • Return on Assets (ttm)

    3.98%

  • Return on Equity (ttm)

    7.98%

  • Revenue (ttm)

    23.57B

  • Net Income Avi to Common (ttm)

    4.06B

  • Diluted EPS (ttm)

    5.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.37B

  • Total Debt/Equity (mrq)

    36.49%

  • Levered Free Cash Flow (ttm)

    5.09B

Research Analysis: DAP.F

View More

Company Insights: DAP.F

Research Reports: DAP.F

View More

People Also Watch